Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers
NCT ID: NCT06408402
Last Updated: 2024-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
1300 participants
OBSERVATIONAL
2024-05-01
2028-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In addition, a blood sample (10 ml on EDTA) will be proposed to the participants to the study
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma
NCT03875079
Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions
NCT05907551
A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma
NCT01164891
PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
NCT01876082
Etiosarc: Environmental Aetiology of Sarcomas From a Multicenter French Population-based Case-control Study Among Adults
NCT03670927
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In addition, a blood sample (10 ml on EDTA) will be proposed to the participants to the study
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cases
Cases: SDHx mutation carriers diagnosed for a SDHx-related tumor
No interventions assigned to this group
Controls
Controls : SDHx mutation carriers with no SDHx-related tumor
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Controls: SDHx mutation carriers with no SDHx-related tumor
Exclusion Criteria
* Patient under tutorship or guardianship or legal safeguard
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
ANSES
OTHER
Centre Leon Berard
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne-Paule Gimenez-Roqueplo, MD, PhD
Role: STUDY_DIRECTOR
Hôpital européen Georges Pompidou - APHP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU d'Angers
Angers, , France
CHU Jean Minjoz Besançon
Besançon, , France
Hôpital Louis Pradel
Bron, , France
CHU de Caen
Caen, , France
Hôpital Michalon - CHU Grenoble
Grenoble, , France
CHU de Lille - Hôpital HURIEZ
Lille, , France
Hopital de la Conception - Marseille
Marseille, , France
CHU de Montpellier - Hôpital Lapeyronie
Montpellier, , France
CHU de Nantes
Nantes, , France
CHU de Nice -Hôpital Archet 2
Nice, , France
Hôpital Pitié-Salpêtrière - APHP
Paris, , France
Hôpital Cochin - APHP
Paris, , France
Hôpital européen Georges Pompidou - APHP
Paris, , France
Hôpital européen Georges Pompidou - APHP
Paris, , France
CHU de Poitiers
Poitiers, , France
CHU de Rennes - Hôpital Sud
Rennes, , France
Hôpitaux universitaire de Strasbourg - Hôpital de Hautepierre
Strasbourg, , France
CHU de Toulouse - Hôpita Larrey
Toulouse, , France
CHU Bretonneau
Tours, , France
Institut Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HGT/MFI/AR245071
Identifier Type: OTHER
Identifier Source: secondary_id
2023-A02297-38
Identifier Type: OTHER
Identifier Source: secondary_id
APHP230878
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.